News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • U.S. August jobs unexpectedly rose 162,000, rekindling markets' odds of a September Fed rate increase.
  • KLA shares jumped 6.9% as a chip-equipment rally pulled buyers back into beaten-down sector names.
  • Lynx says Micron and SanDisk volatility has normalized, positioning both for potential breakouts ahead of executive presentations.
  • ServiceNow fell about 3% as geopolitical U.S.-Iran tensions and profit-taking hit risk appetite.
  • Bitmine shares slipped after a prolonged rally despite a raised price target.
  • U.S. forces used a high-energy laser to disable 11 cartel-linked drones along the southern border.
  • Avalo reported positive Phase 2 data and closed a $375M financing, positioning the stock for a clinical re-rating.

Latest Articles

Dave & Buster's Strengthens Executive Leadership Team to Support Growth, Operational Excellence and Innovation

Dave & Buster's Strengthens Executive Leadership Team to Support Growth, Operational Excellence and Innovation

Dave & Buster's Entertainment, Inc. announces key executive hires and promotions including a new COO, CMO, CTO, Chief Legal Officer, and other leadership roles to support its strategic priorities for growth, operational efficiency, and innovation. These leadership enhancements align with the company’s focus on driving same store sales, EBITDA growt…

Why Rocket Lab Looks Vulnerable: A Mid-Run Short Trade

Why Rocket Lab Looks Vulnerable: A Mid-Run Short Trade

Rocket Lab (RKLB) checks many growth-boxes but trades at a sky-high valuation (roughly 60x trailing sales) while remaining unprofitable and reliant on the unflown Neutron rocket. This trade idea outlines a mid-term short looking to exploit execution and multiple compression risk ahead of key milestones.

GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026

GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026

GRI Bio, a US-based biotech firm specializing in inflammatory and fibrotic diseases, will present compelling Phase 2a data from its oral RAR β/γ-selective agonist, GRI-0621, at the 2026 European Respiratory Society Congress. The data demonstrate favorable lung function improvement, anti-fibrotic biomarker activity, and good tolerability in idiopath…

Novo Nordisk: Cheap Entry Into a Dominant, Resilient Franchise

Novo Nordisk: Cheap Entry Into a Dominant, Resilient Franchise

Novo Nordisk is trading at a valuation that looks unusually cheap for a global leader in diabetes and obesity care. Recent legal wins, a raised full-year outlook and a still-healthy cash-generating core argue for a tactical long. This trade idea gives an entry, stop and target with horizon and risk framing.

Beyond Immerse™ Now Available at Erewhon

Beyond Immerse™ Now Available at Erewhon

Beyond Meat announced the availability of its new functional beverage line, Beyond Immerse, at Erewhon locations across Southern California. This follows previous rollouts in New York and direct-to-consumer channels. Beyond Immerse offers plant-based protein, fiber, antioxidants, and electrolytes in a lightly sparkling drink, expanding Beyond Meat'…

VIVAKOR'S TRADING PLATFORM SURPASSES $2 BILLION MILESTONE

VIVAKOR'S TRADING PLATFORM SURPASSES $2 BILLION MILESTONE

Vivakor, Inc., a Nasdaq-listed integrated energy company, announced that its subsidiary Vivakor Supply & Trading (VST) has exceeded $2.35 billion in annualized commercial activity through crude oil sales. Due to rapid expansion and new commercial opportunities, the company has raised its 2026 outlook for annualized commercial activity to $3.5 billi…

Tyson Foods, Inc. Announces Early Tender Results

Tyson Foods, Inc. Announces Early Tender Results

Tyson Foods, Inc. announced the early results of its tender offers to purchase several series of its senior notes due in 2027 and 2029. The company reported valid tenders exceeding the maximum purchase cap and plans to accept a portion on a pro rata basis. Tyson Foods has also amended the offers by eliminating the 5.400% 2029 tender sub-cap, mainta…

LPL Financial Welcomes Conte Wealth Advisors, LLC

LPL Financial Welcomes Conte Wealth Advisors, LLC

LPL Financial announced the integration of Conte Wealth Advisors, LLC, a family-led firm managing approximately $1.6 billion in assets, into its broker-dealer and Registered Investment Advisor platforms. This move aims to support CWA's growth by leveraging LPL's technology, resources, and scale to attract and empower advisors while enhancing the cl…

/CORRECTION - Ming Shing Group Holdings Limited/

/CORRECTION - Ming Shing Group Holdings Limited/

Ming Shing Group Holdings Limited (NASDAQ: PMA), a Hong Kong-based wet trades and graphene technology company, has entered into a stock purchase agreement to acquire Meals Through Seasons Limited for $510 million payable entirely in company securities. The deal involves issuing 150 million Class A ordinary shares and $360 million in unsecured conve…

SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation

SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation

SciSparc Ltd.'s subsidiary NeuroThera Labs, in collaboration with Clearmind Medicine, has advanced their psychedelic drug pipeline with a newly published U.S. patent application covering a novel combination of MDMA and N-acylethanolamines (such as PEA) for the treatment of PTSD, anxiety, and eating disorders. This patent publication coincides with …

Callan JMB Retains Northern Oil and Gas Founder Michael Reger as President of Callan Power; Northern Oil and Gas Now Valued at Approximately $2.9 Billion

Callan JMB Retains Northern Oil and Gas Founder Michael Reger as President of Callan Power; Northern Oil and Gas Now Valued at Approximately $2.9 Billion

Callan JMB Inc. has appointed Michael Reger, founder and former CEO of Northern Oil and Gas, as President of its new subsidiary Callan Power LLC, focused on oil and gas resource development, energy resilience, and domestic manufacturing of critical electrical equipment. Leveraging Reger's extensive energy industry and public company leadership expe…

RCEL: RECELL Economics Make a Reimbursement-Driven Trade Case

RCEL: RECELL Economics Make a Reimbursement-Driven Trade Case

AVITA's RECELL platform is showing real-world evidence of shorter hospital stays and better healing that should appeal to payers. With a market cap near $300M and recent momentum, a measured long trade targets a re-rate as reimbursement improves. Key risks include legacy reimbursement backlogs, weak liquidity and elevated short interest.

BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval

BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval

BioCardia, a leader in cellular therapeutics for cardiovascular diseases, announced FDA confirmation of Pre-Submission Meeting minutes for its Helix Transendocardial Delivery Catheter. This ratification supports BioCardia's planned follow-on pre-submission intended to enable Helix's approval via the De Novo regulatory pathway, potentially accelerat…

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

Lexicon Pharmaceuticals has earned its third $10 million milestone payment in 2026 from Novo Nordisk following successful patient dosing in the Phase 1 trial of LX9851, a novel oral small molecule for obesity and metabolic disorders. This achievement brings total milestone payments to $75 million out of a potential $1 billion collaboration deal. Th…

La Rosa Holdings Corp. Reports First Half 2026 Results Highlighted by 10% Gross Profit Growth and 42% Improvement in Operating Loss

La Rosa Holdings Corp. Reports First Half 2026 Results Highlighted by 10% Gross Profit Growth and 42% Improvement in Operating Loss

La Rosa Holdings Corp., a US-based real estate and PropTech company, announced first half 2026 financial results marked by a nearly 10% increase in gross profit to $3.7 million and a 42% reduction in operating loss to $4.2 million compared to the prior year. The company also reported a 25% decrease in operating expenses and a 9.4% improvement in ne…